在标签上和标签之外的指示中使用Eptacog Beta的现实世界经验:西班牙的经验
Jose Manuel Martin de Bustamante1, María Isabel Rivas-Pollmar1, Natalia Acedo2
1Department of Haematology, Hospital Universitario la Paz, 28046 Madrid, Spain.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
一种新型重组激活因子VII (rFVIIa) 的eptacog beta,在A型血友病患者使用抑制剂的手术预防和出血治疗中显示出有效性和安全性. 它的使用在第七因子缺乏和获得的血友病例中也很有希望.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙抗体β是一种新型重组激活因子VII (rFVIIa) 药物,其临床前特征与乙抗体α相似.
- 之前的试验 (PERSEPT 1 和 3) 证明了它在使用抑制剂治疗血友病A或B的疗效和安全性,从而获得了FDA和EMA的批准.
- 最近的真实世界数据支持这一群体的积极结果.
研究的目的:
- 评估eptacog beta在标签上和非标签患者群体中的疗效和安全性.
- 为了探索其治疗潜力超出血友病A与抑制剂.
主要方法:
- 两家西班牙医院对eptacogβ使用的回顾性病例系列分析.
- 包括接受药物治疗已批准指示和其他出血障碍的患者.
主要成果:
- 四个病例涉及血友病A和抑制剂 (标签上的使用) 的患者.
- 四个病例涉及获得的血友病患者 (一) 和轻度的因子VII缺乏症患者 (三) (非标签使用).
- 该研究在所有报告的病例中观察到积极的结果.
结论:
- 埃普塔科格β证明了在A型血友病中使用抑制剂进行手术预防和出血治疗的持续有效性和安全性.
- 这份报告是第一个记录了eptacog beta在患有因子VII缺乏和获得血友病的患者中成功使用的报告.
- 这些发现支持将eptacog beta的治疗应用扩展到其他出血疾病.
相关概念视频
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:16Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
143
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
143
01:13Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210
01:26Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K